JP2019135262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019135262A5 JP2019135262A5 JP2019095974A JP2019095974A JP2019135262A5 JP 2019135262 A5 JP2019135262 A5 JP 2019135262A5 JP 2019095974 A JP2019095974 A JP 2019095974A JP 2019095974 A JP2019095974 A JP 2019095974A JP 2019135262 A5 JP2019135262 A5 JP 2019135262A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- compound
- methylumbelliferone
- autoimmune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 208000023275 Autoimmune disease Diseases 0.000 claims 7
- 208000026935 allergic disease Diseases 0.000 claims 7
- 208000012657 Atopic disease Diseases 0.000 claims 6
- 210000003289 regulatory T cell Anatomy 0.000 claims 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 4
- 229940099552 hyaluronan Drugs 0.000 claims 4
- 229920002674 hyaluronan Polymers 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 238000003786 synthesis reaction Methods 0.000 claims 4
- 230000005867 T cell response Effects 0.000 claims 3
- ARQXEQLMMNGFDU-JHZZJYKESA-N 4-methylumbelliferone beta-D-glucuronide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ARQXEQLMMNGFDU-JHZZJYKESA-N 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 230000004060 metabolic process Effects 0.000 claims 2
- 206010003645 Atopy Diseases 0.000 claims 1
- 208000019802 Sexually transmitted disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865084P | 2013-08-12 | 2013-08-12 | |
| US61/865,084 | 2013-08-12 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534801A Division JP2016530265A (ja) | 2013-08-12 | 2014-08-12 | 免疫調節のための４−メチルウンベリフェロン処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019135262A JP2019135262A (ja) | 2019-08-15 |
| JP2019135262A5 true JP2019135262A5 (enExample) | 2019-11-14 |
Family
ID=52468796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534801A Withdrawn JP2016530265A (ja) | 2013-08-12 | 2014-08-12 | 免疫調節のための４−メチルウンベリフェロン処置 |
| JP2019095974A Pending JP2019135262A (ja) | 2013-08-12 | 2019-05-22 | 免疫調節のための４−メチルウンベリフェロン処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534801A Withdrawn JP2016530265A (ja) | 2013-08-12 | 2014-08-12 | 免疫調節のための４−メチルウンベリフェロン処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10285976B2 (enExample) |
| EP (1) | EP3033416A4 (enExample) |
| JP (2) | JP2016530265A (enExample) |
| CN (1) | CN105579578A (enExample) |
| WO (1) | WO2015023691A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9833614B1 (en) | 2012-06-22 | 2017-12-05 | Nevro Corp. | Autonomic nervous system control via high frequency spinal cord modulation, and associated systems and methods |
| US10118904B2 (en) | 2015-06-05 | 2018-11-06 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of Demyelinating Diseases |
| JP6952350B2 (ja) * | 2016-06-10 | 2021-10-20 | 国立大学法人東北大学 | インスリン分泌促進剤又はインスリン抵抗性改善剤 |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| US11278518B2 (en) | 2017-01-13 | 2022-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treatment using 4-methylumbelliferone and derivatives thereof |
| US10370400B2 (en) * | 2017-01-13 | 2019-08-06 | The Board Of Trustees Of The Leland Stanford Junior University | 4-methylumbelliferone derivatives for treatment for immune modulation |
| WO2019165319A1 (en) * | 2018-02-23 | 2019-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | The use of 4-methylumbelliferone to prevent immune rejection in cases of tissue transplantation |
| US20190321641A1 (en) * | 2018-03-29 | 2019-10-24 | Nevro Corp. | Therapeutic modulation to treat blood glucose abnormalities, including type 2 diabetes, and/or reduce hba1c levels, and associated systems and methods |
| CA3123089A1 (en) * | 2018-12-20 | 2020-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Hyaluronan synthesis inhibition for treating autoimmune, inflammatory, fibrotic, or proliferative diseases or disorders |
| EP4048257A1 (en) * | 2019-10-25 | 2022-08-31 | Jessica Kwok | Treatment of conditions of the nervous system |
| WO2021203051A1 (en) * | 2020-04-03 | 2021-10-07 | Standard Of Care Corporation | Aerosolized hyaluronidase and/or 4-methylumbelliferone compositions and methods of using same to treat respiratory diseases or disorders |
| CN114425050A (zh) * | 2022-02-09 | 2022-05-03 | 深圳大学 | 一种4-甲基伞形酮在制备抗过敏药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4451933B2 (ja) * | 1996-12-27 | 2010-04-14 | 住友化学株式会社 | 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法 |
| GB9722600D0 (en) * | 1997-10-24 | 1997-12-24 | Bio Monde Holdings Internation | Pharmaceutical compositon |
| EP1185269B1 (en) | 1999-05-24 | 2007-11-14 | Abaron Biosciences, Inc. | Glycosyltransferase inhibitors |
| JP2004517030A (ja) * | 1999-05-24 | 2004-06-10 | アバロン バイオサイエンシーズ， インコーポレイテッド | グリコシルトランスフェラーゼインヒビター |
| GB0205022D0 (en) * | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
| CA2486302A1 (en) | 2002-05-17 | 2003-11-27 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| WO2004082610A2 (en) * | 2003-03-14 | 2004-09-30 | Brigham And Women's Hospital, Inc. | Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders |
| US20080152640A1 (en) * | 2003-07-29 | 2008-06-26 | Peter Prehm | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer |
| AU2010315057B2 (en) | 2009-11-05 | 2015-05-14 | Sloan Kettering Institute For Cancer Research | Catenae: serosal cancer stem cells |
| CA2806058C (en) * | 2010-07-20 | 2016-09-13 | Halozyme, Inc. | Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| CN108686203A (zh) * | 2012-04-04 | 2018-10-23 | 哈洛齐梅公司 | 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法 |
| CN102846598A (zh) | 2012-08-03 | 2013-01-02 | 广州康臣药物研究有限公司 | 香豆素在制备AGEs形成抑制剂中的应用 |
-
2014
- 2014-08-12 CN CN201480053371.4A patent/CN105579578A/zh active Pending
- 2014-08-12 US US14/911,533 patent/US10285976B2/en active Active
- 2014-08-12 WO PCT/US2014/050770 patent/WO2015023691A2/en not_active Ceased
- 2014-08-12 JP JP2016534801A patent/JP2016530265A/ja not_active Withdrawn
- 2014-08-12 EP EP14836423.5A patent/EP3033416A4/en not_active Withdrawn
-
2019
- 2019-05-03 US US16/403,293 patent/US20200101042A1/en not_active Abandoned
- 2019-05-22 JP JP2019095974A patent/JP2019135262A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019135262A5 (enExample) | ||
| JP2016530265A5 (enExample) | ||
| Sellier-Leclerc et al. | Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome | |
| Sinclair et al. | Salazopyrin in the treatment of rheumatoid arthritis | |
| JP2010527988A5 (enExample) | ||
| JP2017519723A5 (enExample) | ||
| Baratta et al. | Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF) | |
| CN111743891A (zh) | 桑根酮g在制备治疗银屑病的药物中的用途 | |
| Tao et al. | Association of psychological risk factors and acute myocardial infarction in China: the INTER-HEART China study | |
| Lan et al. | Omalizumab for STAT3 hyper-IgE syndromes in adulthood: A case report and literature review | |
| Feldges et al. | Treatment of psoriatic arthropathy with either azathioprine or methotrexate | |
| CN101810642B (zh) | 一种治疗口腔溃疡和急性扁桃体炎的中药制剂及制备方法 | |
| Patterson-Fortin et al. | Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate | |
| Massell et al. | The effect of sulfanilamide on rheumatic fever and Chorea | |
| Collins et al. | Disseminated Mycobacterium haemophilum infection in a 72-year-old patient with rheumatoid arthritis on infliximab | |
| Zang et al. | Toxic epidermal necrolysis in hepatitis A infection with acute-on-chronic liver failure: Case report and literature review | |
| Dixon et al. | Honeycomb lung and chronic rheumatoid arthritis: a case report | |
| Kaiwen et al. | Changes and significance of IL-25 in chicken collagen II-induced experimental arthritis (CIA) | |
| Berkeley et al. | A female with the 48, XXXX karyotype | |
| Foldes et al. | The neuromuscular activity of succinylmonocholine iodide in anaesthetized man | |
| Marchlewicz et al. | The Role of Vitamin D3 Deficiency and Colonization of the Oral Mucosa by Candida Yeast-like Fungi in the Pathomechanism of Psoriasis | |
| Hausfater | Dantrolene and heatstroke: a good molecule applied in an unsuitable situation | |
| Endly et al. | Disseminated cutaneous mycobacterium avium complex in a person with AIDS | |
| Nemet et al. | Results of the follow-up of the former trichinosis patients from Brasov County–Romania | |
| Atamurodovna et al. | CLINICAL FEATURES OF ACUTE RHEUMATIC FEVER IN CHILDREN AT THE PRESENT STAGE |